Klotho Neurosciences Inc USD0.0001

Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).